KR102691705B1 - Composition for lipolysis - Google Patents
Composition for lipolysis Download PDFInfo
- Publication number
- KR102691705B1 KR102691705B1 KR1020210142968A KR20210142968A KR102691705B1 KR 102691705 B1 KR102691705 B1 KR 102691705B1 KR 1020210142968 A KR1020210142968 A KR 1020210142968A KR 20210142968 A KR20210142968 A KR 20210142968A KR 102691705 B1 KR102691705 B1 KR 102691705B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- composition
- parts
- fat
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 230000004130 lipolysis Effects 0.000 title description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract description 42
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 41
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract description 28
- 244000019459 Cynara cardunculus Species 0.000 claims abstract description 24
- 235000019106 Cynara scolymus Nutrition 0.000 claims abstract description 24
- 235000016520 artichoke thistle Nutrition 0.000 claims abstract description 22
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 21
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 21
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 21
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 21
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 21
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 21
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract description 9
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 33
- 230000000052 comparative effect Effects 0.000 description 23
- 238000011156 evaluation Methods 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002366 lipolytic effect Effects 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명의 일 실시예에 따라, 지방 분해용 조성물이 제공된다. 본 발명의 일 실시예에 따른 지방 분해용 조성물은, 소듐 디옥시콜레이트; 및 소듐 하이알루로네이트, L-카르니틴, 에피갈로카테킨 갈레이트, 아티초크 추출물 및 아세틸 헥사 펩타이드-39로 이루어진 군으로부터 선택된 하나 이상을 포함할 수 있다.According to one embodiment of the present invention, a composition for fat decomposition is provided. A composition for fat decomposition according to an embodiment of the present invention includes sodium deoxycholate; And it may include one or more selected from the group consisting of sodium hyaluronate, L-carnitine, epigallocatechin gallate, artichoke extract, and acetyl hexapeptide-39.
Description
본 발명은 지방 분해용 조성물에 관한 것으로서, 구체적으로 소듐 디옥시콜레이트 및 1종 이상의 유효성분을 포함함으로써 피하 또는 피부에 적용 시 지방 분해 효과가 우수하고 통증이 적은 지방 분해용 조성물에 관한 것이다.The present invention relates to a composition for decomposing fat, and more specifically, to a composition for decomposing fat that contains sodium deoxycholate and one or more active ingredients, so that it has an excellent lipolytic effect and causes less pain when applied subcutaneously or on the skin.
최근 식습관, 생활습관, 유전, 환경화학물질 등 다양한 요인에 의하여 현대인들에게 비만이 많이 발생하고 있다. 이에 따라, 비만을 해결하기 위해 운동, 식이요법, 수술, 약물치료 등 다양한 치료 방법들이 등장하고 있다.Recently, obesity is occurring frequently in modern people due to various factors such as eating habits, lifestyle habits, genetics, and environmental chemicals. Accordingly, various treatment methods such as exercise, diet, surgery, and drug treatment are emerging to solve obesity.
특히, 지방을 분해하기 위해 피부에 투여되는 지방 분해용 조성물은 통상적으로 소듐 디옥시콜레이트를 포함한다. 그러나, 소듐 디옥시콜레이트를 포함한 조성물을 피하에 적용 시 통증으로 인하여 고통스럽거나 적용 후 붓기 또는 염증이 발생하는 문제점이 있다.In particular, compositions for fat decomposition administered to the skin to decompose fat typically include sodium deoxycholate. However, when applying a composition containing sodium deoxycholate subcutaneously, there is a problem in that it is painful due to pain or swelling or inflammation occurs after application.
따라서 이와 같은 문제를 해결할 수 있는 지방 분해용 조성물이 요구된다.Therefore, a composition for fat decomposition that can solve this problem is required.
본 발명은 상기 문제점을 해결하기 위한 것으로서, 지방 분해 효과가 우수하고 통증이 적은 지방 분해용 조성물을 제공하는 것을 그 목적으로 한다.The present invention is intended to solve the above problems, and its purpose is to provide a composition for decomposing fat that has excellent lipolytic effect and causes little pain.
본 발명의 기술적 과제들은 이상에서 언급한 기술적 과제들로 제한되지 않으며, 언급되지 않은 또 다른 기술적 과제들은 아래의 기재들로부터 당업자에게 명확하게 이해될 수 있을 것이다.The technical problems of the present invention are not limited to the technical problems mentioned above, and other technical problems not mentioned will be clearly understood by those skilled in the art from the description below.
본 발명의 일 실시예에 따라, 지방 분해용 조성물이 제공된다. 본 발명의 일 실시예에 따른 지방 분해용 조성물은, 소듐 디옥시콜레이트; 및 소듐 하이알루로네이트, L-카르니틴, 에피갈로카테킨 갈레이트, 아티초크 추출물 및 아세틸 헥사 펩타이드-39로 이루어진 군으로부터 선택된 하나 이상을 포함할 수 있다.According to one embodiment of the present invention, a composition for fat decomposition is provided. A composition for fat decomposition according to an embodiment of the present invention includes sodium deoxycholate; And it may include one or more selected from the group consisting of sodium hyaluronate, L-carnitine, epigallocatechin gallate, artichoke extract, and acetyl hexapeptide-39.
또한, 상기 소듐 하이알루로네이트는, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함될 수 있다.Additionally, the sodium hyaluronate may be included in an amount of 0.025 to 1 part by weight based on 100 parts by weight of the sodium deoxycholate.
또한, 상기 L-카르니틴은, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함될 수 있다.Additionally, the L-carnitine may be included in an amount of 0.025 to 1 part by weight based on 100 parts by weight of sodium deoxycholate.
또한, 상기 에피갈로카테킨 갈레이트는, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함될 수 있다.Additionally, the epigallocatechin gallate may be included in an amount of 0.025 to 1 part by weight per 100 parts by weight of the sodium deoxycholate.
또한, 상기 아티초크 추출물은, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함될 수 있다.Additionally, the artichoke extract may be included in an amount of 0.025 to 1 part by weight based on 100 parts by weight of sodium deoxycholate.
또한, 상기 아세틸 헥사 펩타이드-39는, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.01 중량부 이하로 포함될 수 있다.Additionally, the acetyl hexapeptide-39 may be included in an amount of 0.01 parts by weight or less based on 100 parts by weight of sodium deoxycholate.
또한, 소듐 디옥시콜레이트; 및 소듐 하이알루로네이트 또는 L-카르니틴 중 하나 이상을 포함하고, 에피갈로카테킨 갈레이트, 아티초크 추출물 및 아세틸 헥사 펩타이드-39로 이루어진 군으로부터 선택된 하나 이상을 더 포함할 수 있다.Additionally, sodium deoxycholate; and one or more of sodium hyaluronate or L-carnitine, and may further include one or more selected from the group consisting of epigallocatechin gallate, artichoke extract, and acetyl hexapeptide-39.
또한, 소듐 디옥시콜레이트; 및 소듐 하이알루로네이트, L-카르니틴, 에피갈로카테킨 갈레이트 및 아티초크 추출물로 이루어진 군으로부터 선택된 하나 이상을 포함하고, 아세틸 헥사 펩타이드-39를 더 포함할 수 있다.Additionally, sodium deoxycholate; and one or more selected from the group consisting of sodium hyaluronate, L-carnitine, epigallocatechin gallate, and artichoke extract, and may further include acetyl hexapeptide-39.
또한, 상기 지방 분해용 조성물은, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부의 소듐 하이알루로네이트, 0.025 내지 1 중량부의 L-카르니틴, 0.025 내지 1 중량부의 에피갈로카테킨 갈레이트, 0.025 내지 1 중량부의 아티초크 추출물 및 0.01 중량부 이하의 아세틸 헥사 펩타이드-39를 포함할 수 있다.In addition, the composition for fat decomposition includes 0.025 to 1 part by weight of sodium hyaluronate, 0.025 to 1 part by weight of L-carnitine, and 0.025 to 1 part by weight of epigallocatechin gallate, based on 100 parts by weight of sodium deoxycholate. , 0.025 to 1 part by weight of artichoke extract and 0.01 part by weight or less of acetyl hexapeptide-39.
본 발명에 따른 지방 분해용 조성물은 지방 분해 성능이 우수하여 사용자의 미적 만족도를 향상시킬 수 있다.The composition for fat decomposition according to the present invention has excellent fat decomposition performance and can improve the user's aesthetic satisfaction.
또한, 본 발명에 따른 지방 분해용 조성물은 피하 또는 피부에 적용 시 통증이 적으며 붓기와 염증 등의 부작용을 완화시킬 수 있다.In addition, the composition for fat decomposition according to the present invention causes less pain when applied subcutaneously or on the skin and can alleviate side effects such as swelling and inflammation.
본 발명의 상세한 설명에서 인용되는 도면을 보다 충분히 이해하기 위하여 각 도면의 간단한 설명이 제공된다.
도 1은 본 발명의 실시예에 따른 지방 분해 조성물을 볼 부위에 적용하기 전 후의 사진이다.
도 2는 본 발명의 실시예에 따른 지방 분해 조성물을 턱 부위에 적용하기 전 후의 사진이다.
도 3은 본 발명의 실시예에 따른 지방 분해 조성물을 팔 부위에 적용하기 전 후의 사진이다.
도 4는 본 발명의 비교예에 따른 지방 분해 조성물을 턱 부위에 적용하기 전 후의 사진이다.In order to more fully understand the drawings cited in the detailed description of the present invention, a brief description of each drawing is provided.
1 is a photograph before and after applying a lipolytic composition according to an embodiment of the present invention to the cheek area.
Figure 2 is a photograph before and after applying a fat-decomposing composition according to an embodiment of the present invention to the chin area.
Figure 3 is a photograph before and after applying a fat-decomposing composition according to an embodiment of the present invention to the arm area.
Figure 4 is a photograph before and after applying a lipolytic composition according to a comparative example of the present invention to the chin area.
다른 식으로 정의되지 않는 한, 본 명세서에서 사용된 모든 기술적 및 과학적 용어들은 본 발명이 속하는 기술 분야에서 숙련된 전문가에 의해서 통상적으로 이해되는 것과 동일한 의미를 갖는다. 일반적으로, 본 명세서에서 사용된 명명법은 본 기술분야에서 잘 알려져 있고 통상적으로 사용되는 것이다. 또한, 본 발명의 실시예를 설명함에 있어, 관련된 공지 구성 또는 기능에 대한 구체적인 설명이 본 발명의 실시예에 대한 이해를 방해한다고 판단되는 경우에는 그 상세한 설명은 생략한다. 또한, 이하에서 본 발명의 실시예들을 설명할 것이나, 본 발명의 기술적 사상은 이에 한정되거나 제한되지 않고 당업자에 의해 변형되어 다양하게 실시될 수 있다.Unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by a person skilled in the art to which the present invention pertains. In general, the nomenclature used herein is well known and commonly used in the art. Additionally, when describing embodiments of the present invention, if detailed descriptions of related known configurations or functions are judged to impede understanding of the embodiments of the present invention, the detailed descriptions will be omitted. In addition, embodiments of the present invention will be described below, but the technical idea of the present invention is not limited or limited thereto and may be modified and implemented in various ways by those skilled in the art.
본 발명은 지방 분해용 조성물에 관한 것으로서, 소듐 디옥시콜레이트(Sodium Deoxycholate); 및 소듐 하이알루로네이트(Sodium Hyaluronate), L-카르니틴(L-carnitine), 에피갈로카테킨 갈레이트(Epigallocatechin Gallate), 아티초크 추출물(Cynara Scolymus (Artichoke) Leaf Extract) 및 아세틸 헥사 펩타이드-39(Acetyl Hexapeptide-39)로 이루어진 군으로부터 선택된 하나 이상을 포함할 수 있다.The present invention relates to a composition for fat decomposition, comprising: Sodium Deoxycholate; and Sodium Hyaluronate, L-carnitine, Epigallocatechin Gallate, Cynara Scolymus (Artichoke) Leaf Extract, and Acetyl Hexapeptide-39( It may contain one or more selected from the group consisting of Acetyl Hexapeptide-39).
소듐 디옥시콜레이트는 주로 가축의 장에서 추출하는 담즙산 중 하나인 디옥시콜린산(Deoxycholic Acid)의 소듐염으로서, 세포막을 용해시켜 지방 세포의 분해를 유도하고 조성물의 pH를 조절할 수 있다.Sodium deoxycholate is a sodium salt of deoxycholic acid, one of the bile acids mainly extracted from the intestines of livestock. It can dissolve cell membranes, induce decomposition of fat cells, and adjust the pH of the composition.
본 발명의 지방 분해용 조성물은 소듐 디옥시콜레이트에 1종 이상의 유효성분, 즉 소듐 하이알루로네이트, L-카르니틴, 에피갈로카테킨 갈레이트, 아티초크 추출물 및 아세틸 헥사 펩타이드-39 중 1종 이상을 더 포함함으로써 지방 분해 효과를 상승시키고 부작용을 경감시킬 수 있다. The fat-decomposing composition of the present invention contains sodium deoxycholate and one or more active ingredients, namely, one or more of sodium hyaluronate, L-carnitine, epigallocatechin gallate, artichoke extract, and acetyl hexapeptide-39. By further including, the fat decomposition effect can be increased and side effects can be reduced.
소듐 디옥시콜레이트는 지방 분해용 조성물의 총 중량 기준으로 0.01 내지 0.04 중량%, 바람직하게는 0.02 중량%로 포함될 수 있다.Sodium deoxycholate may be included in an amount of 0.01 to 0.04% by weight, preferably 0.02% by weight, based on the total weight of the composition for fat decomposition.
소듐 하이알루로네이트는 주로 닭 벼슬에서 추출되는 히알루론산(Hyaluronic Acid)의 소듐염으로서, 수분 함유량이 높다는 특징이 있어, 피부에 보습을 제공할 수 있고, 피부 깊숙이 침투해 피부 재생 및 탄력을 향상시켜 피부 노화를 방지할 수 있다.Sodium Hyaluronate is a sodium salt of Hyaluronic Acid, mainly extracted from chicken combs. It is characterized by a high moisture content, so it can moisturize the skin and penetrate deep into the skin to improve skin regeneration and elasticity. It can prevent skin aging.
본 발명의 소듐 하이알루로네이트는 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함될 수 있고, 바람직하게는 0.25 내지 0.75 중량부로 포함될 수 있다. 소듐 하이알루로네이트가 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 중량부 미만으로 포함될 경우, 보습과 피부 항노화의 효능이 저하될 수 있고, 소듐 하이알루로네이트가 1 중량부를 초과하여 포함될 경우, 체질에 따라 발진, 가려움, 두드러기 등의 부작용이 발생할 수 있다.Sodium hyaluronate of the present invention may be included in an amount of 0.025 to 1 part by weight, preferably 0.25 to 0.75 parts by weight, based on 100 parts by weight of sodium deoxycholate. If sodium hyaluronate is included in less than 0.025 parts by weight based on 100 parts by weight of sodium deoxycholate, the effectiveness of moisturizing and skin anti-aging may be reduced, and if sodium hyaluronate is included in more than 1 part by weight, the constitution Depending on the condition, side effects such as rash, itching, and hives may occur.
L-카르니틴은 염기성 아미노산인 라이신(Lysine), 메티오닌(Methionine) 및 암모늄이온을 포함하는 비타민 B 복합체 중 하나로, 지방산을 분해시켜 체지방량을 감소시키는 역할을 할 수 있다.L-carnitine is one of the vitamin B complexes containing the basic amino acids Lysine, Methionine, and ammonium ion, and can play a role in reducing body fat mass by breaking down fatty acids.
본 발명의 L-카르니틴은 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함될 수 있고, 바람직하게는 0.25 내지 0.75 중량부로 포함될 수 있다. L-카르니틴이 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 중량부 미만으로 포함될 경우, 지방산 분해의 효능이 저하될 수 있고, L-카르니틴이 1 중량부를 초과하여 포함될 경우, 체질에 따라 메스꺼움, 설사 등 복통이 발생할 수 있다.L-carnitine of the present invention may be included in an amount of 0.025 to 1 part by weight, preferably 0.25 to 0.75 parts by weight, based on 100 parts by weight of sodium deoxycholate. If L-carnitine is included in less than 0.025 parts by weight based on 100 parts by weight of sodium deoxycholate, the effectiveness of fatty acid decomposition may be reduced, and if L-carnitine is included in more than 1 part by weight, nausea, diarrhea, etc. depending on the constitution. Abdominal pain may occur.
에피갈로카테킨 갈레이트는 녹차엽의 추출물인 폴리페놀(Polyphenol) 중 하나로, 피부의 보습을 촉진시키고 강력한 항산화 작용을 통하여 피부 노화를 방지할 수 있다.Epigallocatechin gallate is one of the polyphenols extracted from green tea leaves. It promotes skin moisturization and can prevent skin aging through its powerful antioxidant effect.
본 발명의 에피갈로카테킨 갈레이트는 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함될 수 있고, 바람직하게는 0.25 내지 0.75 중량부로 포함될 수 있다. 에피갈로카테킨 갈레이트가 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 중량부 미만으로 포함될 경우, 보습과 피부 항노화의 효능이 저하될 수 있고, 에피갈로카테킨 갈레이트가 1 중량부를 초과하여 포함될 경우, 체질에 따라 구토, 메스꺼움, 현기증 등 부작용이 발생할 수 있다.Epigallocatechin gallate of the present invention may be included in an amount of 0.025 to 1 part by weight, preferably 0.25 to 0.75 parts by weight, based on 100 parts by weight of sodium deoxycholate. If epigallocatechin gallate is included in less than 0.025 parts by weight based on 100 parts by weight of sodium deoxycholate, the effectiveness of moisturizing and skin anti-aging may be reduced, and if epigallocatechin gallate is included in more than 1 part by weight. Depending on your constitution, side effects such as vomiting, nausea, and dizziness may occur.
아티초크 추출물은 아티초크의 잎에서 추출한 것으로, 담즙의 분비를 촉진하는 특징이 있어 지방 소화 및 분해를 향상시키고, 항산화 효과를 제공하며, 간과 소화 시스템을 보호 및 해독할 수 있다.Artichoke extract is extracted from the leaves of the artichoke and has the characteristic of promoting bile secretion, improving fat digestion and decomposition, providing antioxidant effects, and protecting and detoxifying the liver and digestive system.
본 발명의 아티초크 추출물은 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함될 수 있고, 바람직하게는 0.25 내지 0.75 중량부로 포함될 수 있다. 아티초크 추출물이 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 중량부 미만으로 포함될 경우, 지방 분해, 항산화 및 해독의 효능이 저하될 수 있고, 아티초크 추출물이 1 중량부를 초과하여 포함될 경우, 체질에 따라 알레르기 반응이 발생할 수 있다.The artichoke extract of the present invention may be included in an amount of 0.025 to 1 part by weight, preferably 0.25 to 0.75 parts by weight, based on 100 parts by weight of sodium deoxycholate. If the artichoke extract is included in less than 0.025 parts by weight based on 100 parts by weight of sodium deoxycholate, the effectiveness of fat decomposition, antioxidant and detoxification may be reduced, and if the artichoke extract is included in more than 1 part by weight, it may vary depending on the body constitution. An allergic reaction may occur.
아세틸 헥사 펩타이드-39는 헥사 펩타이드-39를 아세틸화하여 얻은 것으로서, 지방의 축적을 억제하는 역할을 할 수 있다.Acetyl hexapeptide-39 is obtained by acetylating hexapeptide-39 and can play a role in suppressing fat accumulation.
본 발명의 아세틸 헥사 펩타이드-39는 소듐 디옥시콜레이트 100 중량부에 대하여 0.01 중량부 이하로 포함될 수 있다. 아세틸 헥사 펩타이드-39가 0.01 중량부를 초과하여 포함될 경우, 체질에 따라 통증을 유발할 수 있다.Acetyl hexapeptide-39 of the present invention may be included in an amount of 0.01 parts by weight or less based on 100 parts by weight of sodium deoxycholate. If acetyl hexapeptide-39 is included in excess of 0.01 parts by weight, it may cause pain depending on the constitution.
본 발명의 일 실시예에 따르면, 본 발명의 지방 분해용 조성물은 소듐 디옥시콜레이트; 및 소듐 하이알루로네이트 또는 L-카르니틴 중 하나 이상을 포함하고, 이와 더불어 에피갈로카테킨 갈레이트, 아티초크 추출물 및 아세틸 헥사 펩타이드-39로 이루어진 군으로부터 선택된 하나 이상을 더 포함할 수 있다.According to one embodiment of the present invention, the composition for fat decomposition of the present invention includes sodium deoxycholate; and one or more of sodium hyaluronate or L-carnitine, and may further include one or more selected from the group consisting of epigallocatechin gallate, artichoke extract, and acetyl hexapeptide-39.
본 발명의 또 다른 실시예에 따르면, 본 발명의 지방 분해용 조성물은 소듐 디옥시콜레이트; 및 소듐 하이알루로네이트, L-카르니틴, 에피갈로카테킨 갈레이트 및 아티초크 추출물로 이루어진 군으로부터 선택된 하나 이상을 포함하고, 이와 더불어 아세틸 헥사 펩타이드-39를 더 포함할 수 있다. 본 발명의 지방 분해용 조성물은 아세틸 헥사 펩타이드-39를 함께 포함함으로써, 보다 효과적으로 지방을 분해하고 제거하여 사용자의 미적 만족도를 향상시킬 수 있다.According to another embodiment of the present invention, the composition for fat decomposition of the present invention includes sodium deoxycholate; and one or more selected from the group consisting of sodium hyaluronate, L-carnitine, epigallocatechin gallate, and artichoke extract, and may further include acetyl hexapeptide-39. By including acetyl hexapeptide-39, the composition for fat decomposition of the present invention can more effectively decompose and remove fat, thereby improving the user's aesthetic satisfaction.
본 발명의 또 다른 실시예에 따르면, 본 발명의 지방 분해용 조성물은 소듐 디옥시콜레이트와 더불어, 소듐 하이알루로네이트, L-카르니틴, 에피갈로카테킨 갈레이트, 아티초크 추출물 및 아세틸 헥사 펩타이드-39를 함께 포함할 수 있다. 예를 들어, 본 발명에 따른 지방 분해용 조성물은 소듐 디옥시콜레이트 100 중량부에 대하여 소듐 하이알루로네이트 0.025 내지 1 중량부, L-카르니틴 0.025 내지 1 중량부, 에피갈로카테킨 갈레이트 0.025 내지 1 중량부, 아티초크 추출물 0.025 내지 1 중량부 및 아세틸 헥사 펩타이드-39 0.01 중량부 이하로 포함될 수 있다.According to another embodiment of the present invention, the composition for fat decomposition of the present invention includes sodium deoxycholate, sodium hyaluronate, L-carnitine, epigallocatechin gallate, artichoke extract, and acetyl hexapeptide- 39 can be included together. For example, the composition for fat decomposition according to the present invention contains 0.025 to 1 part by weight of sodium hyaluronate, 0.025 to 1 part by weight of L-carnitine, and 0.025 to 1 part by weight of epigallocatechin gallate, based on 100 parts by weight of sodium deoxycholate. It may contain 1 part by weight, 0.025 to 1 part by weight of artichoke extract, and 0.01 part by weight or less of acetyl hexapeptide-39.
바람직하게는, 본 발명에 따른 지방 분해용 조성물은 소듐 디옥시콜레이트 100 중량부에 대하여 소듐 하이알루로네이트 0.5 중량부, L-카르니틴 0.5 중량부, 에피갈로카테킨 갈레이트 0.49 중량부, 아티초크 추출물 0.5 중량부 및 아세틸 헥사 펩타이드-39 0.00025 중량부로 포함될 수 있다.Preferably, the composition for fat decomposition according to the present invention contains 0.5 parts by weight of sodium hyaluronate, 0.5 parts by weight of L-carnitine, 0.49 parts by weight of epigallocatechin gallate, and artichoke based on 100 parts by weight of sodium deoxycholate. It may contain 0.5 parts by weight of extract and 0.00025 parts by weight of acetyl hexapeptide-39.
실시예에 따라, 본 발명에 따른 지방 분해용 조성물은 지방 분해용 주사제, 피부외용제, 화장료 조성물로 이루어진 군에서 선택된 어느 하나의 제형으로 제조되어 피부에 적용될 수 있다.Depending on the embodiment, the composition for fat decomposition according to the present invention may be prepared in any one formulation selected from the group consisting of injections for fat decomposition, external preparations for skin, and cosmetic compositions and applied to the skin.
예를 들어, 본 발명에 따른 지방 분해용 조성물은 초음파기기, 고주파기기, 일렉트로포레이션, 바늘 없는 인젝트 등과 같은 기기를 이용하여 피부에 적용될 수 있다. 또한, 예를 들어, 화장수, 영양로션, 영양크림, 마사지크림, 에센스, 비누, 세정제 등과 같은 화장료 조성물로 제조되어 피부에 도포됨으로써 피부에 적용될 수 있고, 팩, 하이드로젤 슬리밍패치 등과 같은 형태로 제조되어 피부에 부착됨으로써 피부에 적용될 수 있다. 또한, 예를 들어, 미스트, 에어로졸 등과 같은 제형으로 제조되어 피부에 분사함으로써 피부에 적용될 수 있다.For example, the composition for fat decomposition according to the present invention can be applied to the skin using devices such as ultrasonic devices, high-frequency devices, electroporation, needle-less injection, etc. In addition, for example, it can be applied to the skin by being manufactured into cosmetic compositions such as lotion, nutritional lotion, nutritional cream, massage cream, essence, soap, detergent, etc., and manufactured in the form of packs, hydrogel slimming patches, etc. It can be applied to the skin by attaching to it. Additionally, for example, it can be prepared in a formulation such as a mist, aerosol, etc. and applied to the skin by spraying it on the skin.
본 발명의 지방 분해용 조성물은 본 발명의 효과를 해치지 않는 범위 내에서, 당업계에서 통상적으로 사용되는 다른 성분, 예를 들면, pH 조절제, 등장화제, 계면활성제, 안정화제, 보존제, 킬레이트제 및 완충제 중에서 선택된 하나 이상을 추가로 포함할 수 있다. 예를 들어, 본 발명에 따른 조성물은 pH 조절제로 수산화나트륨, 등장화제로 글루코오스, 안정화제로 콜레스테롤, 보존제로 글리세린, 완충제로 시트르산 등을 포함할 수 있다. 다만, 이에 한정되지 않으며, 당업계에서 통상적으로 사용되는 다양한 첨가제 및 일반적으로 지방 분해용 조성물에 포함되는 성분이 추가로 포함될 수 있다.The composition for fat decomposition of the present invention contains other ingredients commonly used in the art, such as pH adjusters, isotonic agents, surfactants, stabilizers, preservatives, chelating agents, and It may additionally include one or more selected from buffering agents. For example, the composition according to the present invention may include sodium hydroxide as a pH adjuster, glucose as an isotonic agent, cholesterol as a stabilizer, glycerin as a preservative, citric acid as a buffer, etc. However, it is not limited to this, and various additives commonly used in the art and components generally included in compositions for fat decomposition may be additionally included.
[실험예][Experimental example]
이하에서, 본 발명을 더욱 구체적으로 설명하기 위한 실시예를 다음과 같이 나타내었으나, 본 발명이 이에 한정되는 것은 아니다.Below, examples are shown to further explain the present invention in more detail, but the present invention is not limited thereto.
실시예와 비교예의 제조Preparation of examples and comparative examples
(1) 실시예 1 내지 3 및 비교예 1 내지 3의 제조(1) Preparation of Examples 1 to 3 and Comparative Examples 1 to 3
하기 표 1에 기재되어 있는 성분을 이용하여, 본 발명에 따른 지방 분해용 조성물의 실시예 및 비교예를 제조하였다. 실시예 1 내지 3, 비교예 2 및 3은 소듐 디옥시콜레이트 100 중량부에 대한 아세틸 헥사 펩타이드-39의 중량부를 변화시킨 지방 분해용 조성물이다. 또한, 비교예 1은 아세틸 헥사 펩타이드-39를 첨가하지 않은 경우의 지방 분해용 조성물이다. 표 1 성분 함량의 단위는 중량부이다.Examples and comparative examples of the composition for fat decomposition according to the present invention were prepared using the components listed in Table 1 below. Examples 1 to 3 and Comparative Examples 2 and 3 are compositions for lipolysis in which the weight parts of acetyl hexapeptide-39 were changed based on 100 parts by weight of sodium deoxycholate. Additionally, Comparative Example 1 is a composition for fat decomposition without adding acetyl hexapeptide-39. The unit of ingredient content in Table 1 is parts by weight.
구체적인 제조방법은 다음과 같다.The specific manufacturing method is as follows.
상기 6종의 성분을 포함한 원료 물질을 용해조에서 배합하고, 43℃의 온도에서 1,500 RPM의 교반 속도로 약 20분간 용해하였다. 이어서, 여과 배출 및 바이알(vial)에 충진한 후, 122℃의 온도, 2.02 bar의 압력으로 20분간 멸균을 수행하여 지방 분해용 조성물을 제조하였다. The raw materials including the above six ingredients were mixed in a dissolution tank and dissolved at a temperature of 43°C and a stirring speed of 1,500 RPM for about 20 minutes. Subsequently, after filtration and filling into a vial, sterilization was performed at a temperature of 122°C and a pressure of 2.02 bar for 20 minutes to prepare a composition for fat decomposition.
실험예: 미적 개선도 및 지방 분해능 평가Experimental example: Evaluation of aesthetic improvement and fat resolution
(1) 실험예 1: 미적 개선도 평가(1) Experimental Example 1: Evaluation of aesthetic improvement
상기 실시예 1 내지 3 및 비교예 1 내지 3에 따른 조성물에 대한 미적 개선도를 평가하였으며, 그 결과를 표 2에 나타내었다.The aesthetic improvement of the compositions according to Examples 1 to 3 and Comparative Examples 1 to 3 was evaluated, and the results are shown in Table 2.
실험방법은 다음과 같다. 글로벌 미적 개선 측도(GAIS, Global Aesthetic Improvement Scale)의 방법을 이용하여, 상기 실시예 및 비교예 샘플을 시험자에게 1주일 간격으로 총 4회 피부에 처치하였다. 마지막 처치로부터 1주 후, 시험자 및 피시험자 각각 30명에게 평가 항목에 만족도를 평가 척도로서 6단계로 평가하도록 하였다. 미적 개선도는 전체 점수를 합산한 평균값을 구한 뒤, 편차를 제외한 값으로 평가하였다.The experimental method is as follows. Using the method of the Global Aesthetic Improvement Scale (GAIS), the samples of the examples and comparative examples were applied to the skin of the tester a total of four times at one-week intervals. One week after the last treatment, 30 testers and 30 test subjects each were asked to rate their satisfaction with the evaluation items in 6 levels as an evaluation scale. The degree of aesthetic improvement was evaluated by calculating the average of all scores and excluding deviations.
실험 결과, 실시예 1 내지 3의 경우, 시험자 및 피시험자의 미적 개선도 평가에서 모두 높은 점수를 획득하여 우수한 만족도를 제공하는 것을 확인할 수 있다.As a result of the experiment, it can be confirmed that Examples 1 to 3 obtained high scores in the aesthetic improvement evaluation of both the tester and the test subject, providing excellent satisfaction.
한편, 아세틸 헥사 펩타이드-39를 첨가하지 않은 비교예 1, 소듐 디옥시콜레이트 100 중량부에 대하여 아세틸 헥사 펩타이드-39가 소량 첨가된 비교예 2 및 아세틸 헥사 펩타이드-39가 과량 첨가된 비교예 3 모두 시험자와 피시험자의 미적 개선도 평가 점수가 낮아, 만족도가 좋지 않음을 확인할 수 있었다.On the other hand, Comparative Example 1 in which acetyl hexapeptide-39 was not added, Comparative Example 2 in which a small amount of acetyl hexapeptide-39 was added relative to 100 parts by weight of sodium deoxycholate, and Comparative Example 3 in which an excessive amount of acetyl hexapeptide-39 was added. It was confirmed that the aesthetic improvement evaluation scores of the tester and the test subject were low, indicating poor satisfaction.
(2) 실험예 2: 지방 분해능 평가(2) Experimental Example 2: Evaluation of fat decomposition ability
상기 실시예 1 내지 3 및 비교예 1 내지 3에 따른 조성물에 대한 지방 분해능을 알아보기 위하여, 실시예 및 비교예의 샘플을 시험자의 턱, 팔 또는 볼 부위의 피부에 적용한 뒤, 1개월 후에 지방의 감소 정도를 육안으로 관찰하였다. In order to determine the fat-decomposing ability of the compositions according to Examples 1 to 3 and Comparative Examples 1 to 3, the samples of Examples and Comparative Examples were applied to the skin of the tester's chin, arm, or cheek area, and after 1 month, the fat was measured. The degree of reduction was observed visually.
실험 결과, 상기 실시예 1 내지 3의 경우, 피부에 적용한 뒤 1개월 후에 턱살, 팔뚝살, 볼살이 눈에 띄게 줄어든 것을 확인할 수 있었다. 실시예 중 대표적으로 실시예 2에 따른 조성물에 대한 지방 분해능의 결과는 도 1 내지 도 3에 나타내었다. 구체적으로, 도 1은 실시예 2에 따른 조성물을 시험자의 볼 부위에 적용하기 전 후의 사진이고, 도 2는 시험자의 턱 부위에 적용하기 전 후의 사진이며, 도 3은 시험자의 팔 부위에 적용하기 전 후의 사진이다.As a result of the experiment, it was confirmed that in Examples 1 to 3, chin fat, arm fat, and cheek fat were noticeably reduced one month after application to the skin. Among the examples, the results of the lipolytic ability of the composition according to Example 2 are shown in Figures 1 to 3. Specifically, Figure 1 is a photograph before and after applying the composition according to Example 2 to the tester's cheek region, Figure 2 is a photograph before and after application to the tester's chin region, and Figure 3 is a photograph of the composition according to Example 2 being applied to the tester's arm region. This is a before and after photo.
한편, 비교예 1 내지 3의 경우, 피부에 적용한 뒤 1개월 후에 턱살, 팔뚝살, 볼살이 줄어들기는 하였으나, 다소 희미하고 더디게 줄어든 것을 확인할 수 있었다. 비교예 중 대표적으로 비교예 1에 따른 조성물에 대한 지방 분해능의 결과는 도 4에 나타내었다. 구체적으로, 도 4는 비교예 1에 따른 조성물을 시험자의 턱 부위에 적용하기 전 후의 사진이다.Meanwhile, in the case of Comparative Examples 1 to 3, it was confirmed that chin fat, arm fat, and cheek fat were reduced one month after application to the skin, but the reduction was somewhat faint and slow. Among the comparative examples, the results of fat decomposition ability for the composition according to Comparative Example 1 are shown in Figure 4. Specifically, Figure 4 is a photograph before and after applying the composition according to Comparative Example 1 to the tester's chin area.
이상으로 본 발명의 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.As the specific parts of the present invention have been described in detail above, those skilled in the art will understand that these specific techniques are merely preferred embodiments and do not limit the scope of the present invention. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (9)
소듐 디옥시콜레이트(Sodium Deoxycholate), 소듐 하이알루로네이트(Sodium Hyaluronate), L-카르니틴(L-carnitine), 에피갈로카테킨 갈레이트(Epigallocatechin Gallate), 아티초크 추출물(Cynara Scolymus (Artichoke) Leaf Extract) 및 아세틸 헥사 펩타이드-39(Acetyl Hexapeptide-39)를 포함하는 것을 특징으로 하는, 지방 분해용 조성물.A composition for fat decomposition,
Sodium Deoxycholate, Sodium Hyaluronate, L-carnitine, Epigallocatechin Gallate, Cynara Scolymus (Artichoke) Leaf Extract ) and acetyl hexapeptide-39 (Acetyl Hexapeptide-39). A composition for fat decomposition.
상기 소듐 하이알루로네이트는, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함되는 것을 특징으로 하는, 지방 분해용 조성물.According to claim 1,
A composition for fat decomposition, characterized in that the sodium hyaluronate is contained in an amount of 0.025 to 1 part by weight based on 100 parts by weight of the sodium deoxycholate.
상기 L-카르니틴은, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함되는 것을 특징으로 하는, 지방 분해용 조성물.According to claim 1,
A composition for fat decomposition, characterized in that the L-carnitine is contained in an amount of 0.025 to 1 part by weight based on 100 parts by weight of the sodium deoxycholate.
상기 에피갈로카테킨 갈레이트는, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함되는 것을 특징으로 하는, 지방 분해용 조성물.In paragraph 1,
A composition for fat decomposition, characterized in that the epigallocatechin gallate is contained in an amount of 0.025 to 1 part by weight based on 100 parts by weight of the sodium deoxycholate.
상기 아티초크 추출물은, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부로 포함되는 것을 특징으로 하는, 지방 분해용 조성물.According to claim 1,
The artichoke extract is contained in an amount of 0.025 to 1 part by weight based on 100 parts by weight of sodium deoxycholate.
상기 아세틸 헥사 펩타이드-39는, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.0001 내지 0.01 중량부로 포함되는 것을 특징으로 하는, 지방 분해용 조성물.According to claim 1,
A composition for fat decomposition, characterized in that the acetyl hexapeptide-39 is contained in an amount of 0.0001 to 0.01 parts by weight based on 100 parts by weight of the sodium deoxycholate.
상기 지방 분해용 조성물은, 상기 소듐 디옥시콜레이트 100 중량부에 대하여 0.025 내지 1 중량부의 소듐 하이알루로네이트, 0.025 내지 1 중량부의 L-카르니틴, 0.025 내지 1 중량부의 에피갈로카테킨 갈레이트, 0.025 내지 1 중량부의 아티초크 추출물 및 0.0001 내지 0.01 중량부의 아세틸 헥사 펩타이드-39를 포함하는 것을 특징으로 하는, 지방 분해용 조성물.According to claim 1,
The composition for fat decomposition includes 0.025 to 1 part by weight of sodium hyaluronate, 0.025 to 1 part by weight of L-carnitine, 0.025 to 1 part by weight of epigallocatechin gallate, 0.025 to 1 part by weight, based on 100 parts by weight of sodium deoxycholate. A composition for fat decomposition, comprising from 1 part by weight of artichoke extract and 0.0001 to 0.01 parts by weight of acetyl hexapeptide-39.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210142968A KR102691705B1 (en) | 2021-10-25 | 2021-10-25 | Composition for lipolysis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210142968A KR102691705B1 (en) | 2021-10-25 | 2021-10-25 | Composition for lipolysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20230059197A KR20230059197A (en) | 2023-05-03 |
| KR102691705B1 true KR102691705B1 (en) | 2024-08-06 |
Family
ID=86380660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210142968A KR102691705B1 (en) | 2021-10-25 | 2021-10-25 | Composition for lipolysis |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102691705B1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10361067A1 (en) * | 2003-12-22 | 2005-07-14 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of fat accumulations |
| US9144556B2 (en) * | 2011-01-21 | 2015-09-29 | Lion Corporation | Composition for promoting lipolysis |
| US20180243211A1 (en) * | 2015-08-28 | 2018-08-30 | Caliway Biopharmaceuticals Co., Ltd. | A pharmaceutical composition for reducing local fat and uses thereof |
| KR101841193B1 (en) * | 2016-09-22 | 2018-03-22 | 이경락 | Composition for hypotonic lipolysis and manufacturing method thereof |
| KR20210079570A (en) * | 2019-12-20 | 2021-06-30 | 주식회사 에이엠메딕스 | Lipolytic substance and the manufacturing method thereof |
-
2021
- 2021-10-25 KR KR1020210142968A patent/KR102691705B1/en active IP Right Grant
Non-Patent Citations (1)
| Title |
|---|
| INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, VOL. 23, NO. 2, PP.481-489, 2010.04.01 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230059197A (en) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106265348B (en) | Substrate with skin barrier repairing and anti-aging effects and preparation method and application thereof | |
| CN110772463B (en) | Eye skin repair composition and preparation method and application thereof | |
| KR101700903B1 (en) | Anti-wrinkle cosmetic composition containing centella asiatica extract, timosaponin, hyaluronic acid, collagen | |
| CN109846740B (en) | Skin care composition and preparation method and application thereof | |
| KR102276289B1 (en) | Composition for hair | |
| KR102071627B1 (en) | Peeling gel composition for removing keratin of skin and manufacturing method thereof | |
| WO2003037291A1 (en) | Cream for treatment of skin injured by the sun | |
| KR102475897B1 (en) | Mask cosmetic composition comprising Graviola antibiotic extract and method of preparing the same | |
| AU2002318699A1 (en) | Cream for treatment of skin injured by the sun | |
| KR101277530B1 (en) | Composition for scalp-care before haircoloring | |
| CN112691070A (en) | Anti-aging composition, eye cream and preparation method thereof | |
| EP3290053B1 (en) | Topical composition comprising oxybutynin for the treatment of hyperhidrosis | |
| KR102373929B1 (en) | Cosmetics composition for scalp care in natural shampoo and essence comprising mixed ferment extracts of natural products | |
| JP2023097373A (en) | Schizophyllan composition as well as preparation method and application thereof | |
| KR20190001136A (en) | Composition of face-lifting pack for improving skin condition comprising oligopeptides | |
| KR102691705B1 (en) | Composition for lipolysis | |
| KR20100005481A (en) | Composition for improving scalp and hair condition | |
| CN110917058A (en) | Cosmetic agent for relieving skin irritation and preparation method thereof | |
| KR100917673B1 (en) | Hair loss prevention or hair growth composition containing caffeine-containing cation / anionic surfactant mixed vehicle | |
| CN106963672B (en) | Composition capable of relieving visual fatigue and periocular skin cell fatigue and application thereof | |
| KR101667308B1 (en) | Anti-wrinkle cosmetic composition containing timosaponin, hyaluronic acid, collagen, calendula flower extract | |
| CN111939113A (en) | Multi-effect eye muscle activating base solution and preparation method thereof | |
| CN114224749B (en) | Facial mask and preparation method thereof | |
| CN114288391B (en) | Antibacterial and anti-inflammatory lotion for women and preparation method thereof | |
| KR102532994B1 (en) | Costmetic compostions for skin lifing Manufacturing method thereof and O/W type cosmetics containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20211025 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230904 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240709 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240731 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240731 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |